Home Healthcare Crispr Associated Cas Genes Market
crispr associated cas genes market

CRISPR & Cas Genes Market Size, Share & Trends Analysis Report, By Product & Service (Product {Kits & Enzymes, Libraries, Design Tool, Antibodies, Others}, Service {Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis}); By Application; By End Use; and By Region; Segment Forecasts, 2021 - 2029

  • Published Date: Nov 2021
  • Pages: 132
  • Format: PDF
  • Report ID: PM1738
  • Base Year: 2020
  • Historical Data: 2017 - 2019

Report Summary

The global CRISPR & Cas genes market was valued at USD 1.60 billion in 2020 and is expected to grow at a CAGR of 18.2% during the forecast period. Technology advancement and increasing acceptance in various fields of biotechnology, such as researching epigenetics and healthcare, expanding human germline altering, and providing a tool for descriptive and analytical plant genome formatting, is anticipated to fuel the genes market growth during the forecast period.

CRISPR/Cas is a novel technique that allows scientists to manipulate genes regions by deleting, inserting, or modifying DNA sequences. CRISPR is an abbreviation for clustered routinely interspaced small palindromic repetitions found in the genomes of some microorganisms. It is quicker and much more precise than conventional DNA editing procedures and has a wider variety of possible uses.

CRISPR & Cas Genes Market ReportKnow more about this report: request for sample pages

The coronavirus outbreak is projected to benefit this genes market by increasing the market for COVID-19 screening procedures. The pandemic has moved scientists' attention to establishing COVID-19 genetic diagnostic equipment relying on this technique.

In March 2021, for example, scientists from Nanyang Technological University in Asia created a CRISPR-based coronavirus testing that produces findings in 30 minutes. The test checks the virus after it has mutated. It would inspire other parties to take advantage of the chance.

Furthermore, for instance, according to the Genetic Engineering & Biotechnology News August 2020 release, CRISPR genes startup companies such as Intellia Therapeutics and Editas Medicine are involved in developing new and exotic enzymes through genome editing for growing vegetables that have better taste and also diagnose COVID-19 through the availability of minimal resources.

Industry Dynamics

Growth Drivers
Substantial funding raised by the key market players to boost the development and advancement of the CRISPR Cas9 genes-editing technique drives the global market growth. For instance, in January 2020, Mammoth Biosciences has raised nearly USD 45 million of strategic funding, bringing its overall budget to over USD 70 million to be used in the development of its CRISPR genes-driven diagnostics capabilities.

Moreover, due to technical advancements and their future uses, rivalry among current businesses has intensified. The highly flexible CRISPR/Cas genes innovation has received significant attention. Merck KGaA, for example, had secured several 26 CRISPR trademarks globally until May 2020. This demonstrates that biotechnology businesses are increasingly focusing on CRISPR/Cas genes technologies.

Challenges
The high costs connected with CRISPR genes usage are projected to impede worldwide market growth to some extent. Furthermore, ethical concerns about human genome editing are projected to stifle growth in the global CRISPR & Cas genes market throughout the forecast period.

Report Segmentation

The market is primarily segmented on the basis of product & service, by application, by end-use, and geographic region.

By Product & Service

By Application

By End-Use

By Region

  • By Product
    • Kits & Enzymes
      • Vector-based Cas
      • DNA-free Cas
    • Libraries
    • Design Tool
    • Antibodies
    • Others
  • By Service
    • Cell Line Engineering
    • gRNA Design
    • Microbial Gene Editing
    • DNA Synthesis

 

  • Biomedical
    • Genome Engineering
    • Disease Model Studies
    • Functional Genomics
    • Epigenetics
    • Others
  • Agricultural
  • Biotechnology & Pharmaceutical Companies
  • Academics & Government Research Institutes
  • Contract Research Organizations (CROs)
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • MEA (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: request for sample pages

Insight by Application

In 2020, the biomedical segment accounted for 86.5% of the revenue share in the global market. The increasing use of CRISPR & Cas genes-editing techniques in several fields of biomedical studies has mainly contributed to this field's outstanding income. A detailed analysis of the biomedical segment is expected to propel the sector's growth throughout the projection period.

Furthermore, the use of nano-carriers and the development of new delivery methods have substantially increased the effectiveness and uniqueness of this technology. The story of CRISPR/Cas9 nuclease enables precise and straightforward genome modification. As a result, the genes and tissue engineering fields would directly influence the usage of CRISPR genome engineering.

Insight by End-use

The biotechnology & pharmaceutical segment is expected to grow at a CAGR of 18.3% in the global market. Pharmaceutical businesses are increasingly utilizing CRISPR-Cas9 to create better biological forms employed for human illnesses in less period and accelerate the detection and validation of the most recent therapeutic aims. As a result, the presence of a significant clinical pipeline based on CRISPR genes-editing knowledge is expected to expand the genes market.

Furthermore, as cell therapy treatments gain traction, there is an increased requirement for CRISPR-based genomic methods to create innovative therapeutics. As a result, contract research institutes firms are likely to see significant market expansion throughout the projected timeline. In this industry, intense rivalry among competitors, emphasizing speed and disposal costs, is projected to affect the CRISPR and Cas genes market.

Geographic Overview

Geographically, North America market accounted for 45.5% of the revenue share in 2020 due to many pharmaceutical companies that are involved in developing new and targeted therapeutics by using genes-editing tools. For instance, in May 2020, Merck has received approval for two of its CRISPR Cas9 driven genes-editing patents in the U.S. This critical approval would allow Merck to proactively support the scientists and researchers in the U.S. to boost the development of genes therapy-based therapeutics.

Additional funding for development efforts to deliver modified goods to prevent chronic illnesses is expected to fuel the expansion of the CRISPR & Cas genes market in North America. During the forecast period, the industry in Asia Pacific is expected to expand the most in terms of revenue. A major driver predicted to promote market expansion in the area and over forecast timeframe is the rising incidence of different genetic illnesses, along with increased government funding in research & development activities to discover innovative therapies.

Moreover, Setsuro Technology, a Japanese biotech business, received a CRISPR-Cas9 patent from Dublin-based ERS Genetics in March 2021. Depending on this approach, the Japanese business is building cellular and animal prototypes. Such activities are expected to expand the country's use of CRISPR-Cas9 technology, resulting in considerable income generating over the forecast period, which in turn will increase the genes market share in Asia Pacific in the coming years.

Competitive Insight

Market players operating in the global genes market are Add gene, AstraZeneca plc. Beam Therapeutics, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Cibus, Danaher Corporation, Editas Medicine, Inc., eGenesis, F. Hoffmann-La Roche Ltd., GenScript, Hera Bio Labs, Horizon Discovery Group plc, Inscripta, Inc., Intellia Therapeutics, Inc., Intellia Therapeutics, Inc., Lonza, Mammoth Biosciences, Merck KGaA, OriGene Technologies, Inc., PLANTeDIT, Recombine tics, Inc., Synthego, Takara Bio Inc., Thermo Fisher Scientific, Inc., Vertex Pharmaceuticals Incorporated.

The market is witnessing increased competition as a result of the expanding functional background and technological advancements. This has resulted in the entrance of other enterprises in this market, which has increased competition. These enterprises are collaborating with foreign corporations to develop novel product offerings and increase their market presence. For instance, Caribou Biosciences, Inc., a significant clinical CRISPR genome engineering company, reported in March 2021 that this had closed a USD 115 million Round C funding.

CRISPR & Cas Genes Market Report Scope

Report Attributes

Details

Market size value in 2020

USD 1.60 billion

Revenue forecast in 2029

USD 7.24 billion

CAGR

18.2% from 2021 - 2029

Base year

2020

Historical data

2017 - 2019

Forecast period

2021 - 2029

Quantitative units

Revenue in USD million/billion and CAGR from 2021 to 2029

Segments covered

By Product & Service, By Application, By End-use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Companies

Add gene, AstraZeneca plc. Beam Therapeutics, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Cibus, Danaher Corporation, Editas Medicine, Inc., eGenesis, F. Hoffmann-La Roche Ltd., GenScript, Hera Bio Labs, Horizon Discovery Group plc, Inscripta, Inc., Intellia Therapeutics, Inc., Intellia Therapeutics, Inc., Lonza, Mammoth Biosciences, Merck KGaA, OriGene Technologies, Inc., PLANTeDIT, Recombine tics, Inc., Synthego, Takara Bio Inc., Thermo Fisher Scientific, Inc., Vertex Pharmaceuticals Incorporated.

 

Key Take-Away
Polaris Market Research
CRISPR & Cas Genes Market Size, Share | Global Industry Report, 2029